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Background: Effective interventions to improve the outcome of patients subjected to 
myocardial ischemia reperfusion (MI/R) are urgent in clinical settings. Tanshinone IIA (TSA) is 
reported to attenuate myocardial injury and improve ventricular remodeling post MI/R. Here, 
we evaluated the efficacy of AFC1 compound that is similar to TSA structure  in murine MI/R 
models. We found that AFC1 had a comparable effect of improving murine cardiac function 
after MI/R while it was superior to TSA in safety profile. Administration of AFC1 reduced 
reactive oxygen species (ROS) production, inflammatory cells infiltration, and the expression 
of platelet derived growth factor receptors (PDGFR) in infarcted myocardium. Treatment 
with AFC1 also attenuated MI/R-induced cardiac remodeling and contributed to the 
recovery of cardiac function. Additionally, AFC1 reversed the elevation of PDGFR expression 
induced by PDGF-AB in both neonatal rat cardiomyocytes (NCMs) and neonatal rat cardiac 
fibroblasts (NCFs) and suppressed PDGF-AB induced NCM hypertrophy via STAT3 
pathway and NCF collagen synthesis through p38-MAPK signaling in vitro. Similarly, AFC1 
may contribute to the recovery of cardiac function in mice post MI/R via suppressing STAT 
signaling. Our results confirmed that AFC1 exerts anti-hypertrophic and anti-fibrotic effects 
against MI/R-induced cardiac remodeling, and suggest that AFC1 may have a promising 
potential in improving the outcome of patients who suffered from MI/R.
Keywords: AFC1 compound, myocardial ischemia reperfusion, platelet derived growth factor, platelet derived 
growth factor receptor, ventricular remodeling
INTRODUCTION
Ischemic heart disease (IHD) has been a leading cause to high morbidity and mortality in developed 
countries with increasing incidence in developing countries (Chan et al., 2011). Although timely 
intervention can restore coronary flow, the reperfusion process triggers myocardium injury (Yellon 
and Hausenloy 2007), known as myocardial ischemia reperfusion (MI/R) injury, and cardiac 
remodeling, and subsequent heart failure (HF), which are the predominant contributors of death 
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worldwide (Murdoch et al., 2006; Sun, 2009; Wang et al., 2015a). 
Therefore, effective prevention and treatment strategies to 
attenuate or reverse MI/R-induced remodeling is of great clinical 
value in IHD patients.
Recently, the protective role and relatively less adverse 
reaction of traditional Chinese medicine (TCM) in IHD have 
been highlighted. Danshen, the dry roots and rhizome of 
Salvia miltiorrhiza Bge., has been widely used either alone or 
in combination with other herbal ingredients for patients with 
IHD and other cardiovascular diseases in both China and other 
countries because of its efficacy in improving microcirculation 
and protecting against myocardial ischemia (Cheng, 2007). For 
example, results from meta-analysis demonstrated the potential 
benefits of compound Danshen dripping pill (CDDP) for treating 
coronary heart disease (Luo et al., 2015; Huang et al., 2016). 
However, the overall quality of the evidences in the systematic 
reviews was poor and high-quality evidence is warranted to support 
the clinical application of CDDP in treating IHD. Tanshinone 
IIA (TSA) is the most abundant and active diterpenoid quinone 
compound among lipophilic components extracted from Danshen 
(Wu et al., 2013). It is reported that TSA can attenuate myocardial 
injury and improve ventricular remodeling post MI/R via reducing 
reactive oxygen species (ROS) generation in mitochondria (Zhou 
et al., 2003; Jin and Li, 2013; Jin et al., 2013). However, in clinical 
settings, the efficacy of TSA is limited because of its lipid-soluble 
property, low bioavailability, and short half-life (Liu et al., 2013). 
Therefore, TSA modification targeting the above shortcomings is a 
promising strategy for its development in MI/R therapy.
Recently our team has investigated various compounds with 
similar core structure of TSA, including AFC1. In this study, 
we proved its potential role in cardiac protective effect against 
cardiac cell injury, hypertrophy, and fibrosis in vitro and in 
vivo. Thus, AFC1 compound may become a novel therapeutic 
pharmaceutical for patients subjected to MI/R. Accordingly it 
is important to study the effect of AFC1 in vivo to evaluate its 
efficacy and possible mechanism of actions.
Previous studies have demonstrated the importance of growth 
factors in IHD (Liu et al., 2014; Pello et al., 2015). High level 
of platelet derived growth factor (PDGF) in infarcted hearts 
contributed to myocardial inflammation and fibrosis in rats (Zhao 
et al., 2011). PDGF family is composed of four kinds of isoforms, 
-A, -B, -C, and -D, which comprised homodimers of PDGF-AA, 
-BB, -CC, and –DD and heterodimer of PDGF-AB (Price 
et  al., 2003). PDGF exerts its biological activities through two 
distinct subtypes of tyrosine kinase receptors, PDGF receptors 
(PDGFR)-α and -β expressed on cardiomyocytes (Vantler et al., 
2010). Excessive expression of PDGF could result in deposition 
of extracellular matrix and further induces cardiac remodeling 
(Vantler et al., 2010; Zhao et al., 2011). PDGF could induce 
H2O2 (kind of ROS) generation in mouse embryonic fibroblasts 
(MEFs) by binding PDGFR (Choi et al., 2005). On the other 
hand, the inhibition of PDGF/PDGFR pathway could attenuate 
the vascular remodeling via reducing the inflammatory response 
in the hypertensive rat with myocardial fibrosis (Fan et al., 2013). 
Therefore, PDGF/PDGFR may promote the development of 
cardiac remodeling after MI/R by mediating oxidative stress and 
inflammatory response.
Our present study demonstrated for the first time that 
treatment with AFC1 compound effectively attenuates MI/R-
induced cardiac remodeling, accompanied by decreased PDGFR 
expression, oxidative stress, and inflammatory response in 
hearts post MI/R. Moreover, AFC1 compound inhibited NCM 
hypertrophy and NCF collagen synthesis induced by PDGF-AB 
and contributed to the recovery of cardiac function post MI/R 
via regulating STAT3 pathway.
MATERIALS AND METHODS
Animals
Specific pathogen-free, male C57BL/6 mice (8–10 weeks) were 
purchased from Slac Laboratory Animal Co. Ltd (Shanghai, 
China). All experiments were conducted in accordance with 
protocols approved by the Institutional Animal Care and Use 
Committee of Tongji University.
Establishment of Myocardial Ischemia 
Reperfusion Murine Models
Echocardiography was performed before the establishment of 
MI/R models. Mice with EF above 50% were included in the in 
vivo experiment. MI/R models were established as described 
previously (Pu et al., 2013). Regional ischemia was achieved 
by ligation of LAD using a 10-0 silk suture with a section of 
silica gel tube. Successful myocardial ischemia was achieved 
when the anterior wall of the left ventricular (LV) turned pale. 
After 30 min of ischemia, the ligation was relieved and the 
successful reperfusion was confirmed by epicardial hyperemia. 
TSA (5 mg/kg) or AFC1 compound (7 or 14 mg/kg) were 
intraperitoneally administrated daily for 1 week following 
MI/R. Mice with the heart exposed through left thoracic 
incision without ligation of left anterior descending coronary 
artery (LAD) were included in the sham group. Mice with 
LAD ligation for 30 min and then reperfusion for 2 weeks were 
randomly assigned to the following groups (5 mice in each 
group): Sham, MI/R, MI/R+TSA (5 mg/kg), MI/R+AFC1-L 
(7 mg/kg), and MI/R+AFC1-H (14 mg/kg). Each experiment 
was repeated at least three times. The AFC1 compound was 
synthesized by CG LI’s lab at Western Sydney University.
Echocardiography
On day 14 post MI/R, the mice were anesthetized using 
isoﬂurane then M-mode echocardiography was performed in 
mice with echocardiographic imaging system (Visualsonics, 
Canada) equipped with a 15-MHz linear transducer. Parameters 
of cardiac function were measured digitally on the M-mode 
tracings. All echocardiographic procedures were performed by 
a qualified investigator who was blinded to the grouping and 
treatment. The long-axis and short-axis view in B-mode were 
obtained. The B-mode guided M-mode view at the papillary 
muscle level was obtained for the evaluation of parameters. The 
end-systolic and end-diastolic LV dimensions were captured to 
calculate the LV ejection fraction (EF) and fractional shortening 
(FS) as previously described (Lin et al., 2013).
AFC1 Compound Attenuated MI/R-Induced RemodelingLiu et al.
3 October 2019 | Volume 10 | Article 1142Frontiers in Pharmacology | www.frontiersin.org
Histology
After the reperfusion, fresh heart biopsies were fixed in 4% 
paraformaldehyde overnight at 4°C and embedded in paraffin. 
Sections into 5-μm slices were stained with hematoxylin-eosin 
(H&E) or Masson’s trichrome for assessment of fibrosis. Tissues 
for immunofluorescence were submerged in liquid nitrogen and 
then embedded in optimal cutting temperature (OCT) solution 
(Sakura Finetek, USA) on dry ice to be frozen completely. 
Cardiomyocyte hypertrophy was examined in the peri-infarct 
zone. Myocyte cross-sectional areas were measured using Image J 
software (National Institutes of Health) in frozen sections stained 
with 5 μg/ml wheat germ agglutinin (WGA-Alexa Fluor® 488 
conjugate, Invitrogen, USA). Five parts were chosen in the WGA 
images (200X) including left top, right top, middle, left bottom, 
and right bottom, and six cells were analyzed for each part. In 
other experiments, the hearts were excised for Masson staining 
to evaluate the cardiac remodeling. For inflammatory cell 
infiltration and PDGFR protein expression, immunofluorescence 
staining with anti-CD45 (Cell Signaling Technology, USA) 
and anti-PDGFRα (Cell Signaling Technology, USA) in frozen 
sections was conducted. Then the number of CD45+ cells/
field were quantified by Image J software (National Institutes of 
Health, USA).
ROS Production
ROS production was evaluated with dihydroethidium (DHE, 
Sigma, USA) on frozen myocardial sections. Heart slices were 
incubated at 37°C for 30 min with 10 μmol/L DHE in phosphate-
buffered saline (PBS). Staining was captured by fluorescence 
microscope (Leica, Germany). Fluorescence intensity was 
quantified by using Image J software (National Institutes of 
Health, USA).
Isolation and Culture of Primary 
Cardiomyocytes and Cardiac Fibroblasts
NCM and NCF were isolated from 1-day-old pups with 
enzymatic digestion as described previously (Thomas et al., 
2002; Tzanidis et al., 2003). Purified NCMs were seeded at high 
density of 1×106 in 6-well plate and 3×105 in 12-well plate and 
maintained in serum-free DMEM (Gibco, USA) supplemented 
with 5 mg/ml insulin, 10 mg/ml apo-transferrin, and 50 mM 
KCl. Bromodeoxyuridine (0.1 mM, Sigma, USA) was applied 
for the first 3 days. NCF were seeded at a density of 3×105 
in 6-well plate and 5×104 in12-well plate and cultured in 
DMEM HG supplemented with 0.5% BSA and 1% L-ascorbic 
acid (Sigma, USA). On the fourth day, 1 h after pretreatment 
with AFC1 (0.1, 1.0, 3.0, 10.0 μM), PDGF-AB (10 ng/ml, 
PEPROTECH, USA) was added to induce hypertrophy in 
NCM and collagen synthesis in NCF. After 48 h of PDGF-AB 
stimulation, cells were harvested to determine hypertrophy 
and fibrosis, defined as a significant increase in protein content 
via 3H-Leucine or 3H-Proline incorporation. Cells were treated 
with AFC1 or DMSO for 1 h and then PDGF-AB for another 15 
min for protein sample collection and Western blot detection.
3H-Leucine and 3H-Proline Incorporation
On the fourth day, after addition of PDGF-AB, NCMs were 
labeled with 3H-Leucine (1 μCi) and NCF with 3H-Proline (5 μCi) 
(PerkinElmer, USA) for 48 h. The experiment was terminated by 
washing the cells with cold PBS for three times then precipitating 
with 10% trichloroacetic acid (TCA, Sigma, USA) for 30 min. 
Cells were then lysed in 1 M NaOH overnight in 4°C. After 
neutralization with 1 M HCl and addition of scintillation fluid 
(PerkinElmer, USA), radioactivity was captured in a liquid 
scintillation counter (HIDEX 300 SL, Finland). The results 
represent at least three separate experiments done in triplicate 
for each condition.
MTT Assay
Cell viability was determined with colorimetric method using 
the MTT assay. NCFs were seeded at a density of 1.5×103 and 
human umbilical vein endothelial cells (HUVECs, PromoCell) 
at 1×104 cells per well in 96-well plate. After treatments 
for 48 h, cells were incubated with 10 μl of 5 mg/ml MTT 
(3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H tetrazolium 
bromide (Sigma, USA) solution at 37°C for 4 h. The formazan 
crystals were dissolved in 100 μl of isopropanol for 20 min at 
37°C, and absorbance at 570 nm was detected on a Microplate 
Reader (SpectraMax, USA).
Quantitative RT-PCR (q-PCR)
Total RNA (1 μg) extracted from myocardium, NCM, and NCF 
were reverse transcribed with PrimeScript RT reagent Kit with 
gDNA Eraser (TaKaRa, Japan), and q-PCR was performed on the 
7900HT Fast Real Time PCR System (Applied Biosystems, UK) 
with the SYBR mastermix (Applied Biosystems, UK). All primer 
sequences were listed in Table 1.
Comparison of gene expression in different samples was 
calculated as follows. Each sample was related to an internal 
control gene (GAPDH). For example, Sample A was the control 
sample and Sample B was the treated one.
ΔΔCt = (Ct gene of interest - Ct GAPDH)sample B - (Ct gene of 
interest - Ct GAPDH)sample A.
Finally, relative quantification of gene expression (Sample 
B) = 2-ΔΔCt.
Western Blot
Protein was extracted from NCM, NCF, and homogenized 
myocardium tissue in lysis buffer. Protein lysate concentrations 
were determined via Pierce BCA Protein Assay Kit (Termo 
Scientific, USA). Equal amount of protein sample (20–30 μg/
lane) from each group was subjected to 10% SDS-PAGE and 
transferred onto nitrocellulose membranes. After blocking 
with 5% bovine serum albumin (BSA), membranes were 
incubated overnight with primary antibodies (1:1,000, Cell 
Signaling Technology, USA) against p-JAK2, p-STAT3, 
STAT3, p-p38, GAPDH, and pan-actin. On the second day, 
the membranes were incubated with fluorescent secondary 
antibody DyLight 800-Goat Anti-Rabbit IgG (H+L) (KPL, 
AFC1 Compound Attenuated MI/R-Induced RemodelingLiu et al.
4 October 2019 | Volume 10 | Article 1142Frontiers in Pharmacology | www.frontiersin.org
USA). The membranes were scanned by ODYSSEY infrared 
imaging system (LI-COR Biosciences, USA). After incubation 
of phosphorylated proteins, we used stripping buffer 
(beyotime, China) to extract antibodies. Then we did the 
blocking and the following incubation procedures to obtain 
total protein quantification.
Statistical Analysis
Data, all presented as mean ± SEM, were analyzed using SPSS 
software, version 11.0 (SPSS Inc., Chicago, IL, USA). For in vivo 
experiments, the Mann-Whitney U test was used for comparisons 
between different groups. One-way analysis of variance with a 
Bonferroni post hoc test was used for multiple comparisons. 
P < 0.05 was considered statistically significant.
RESULTS
Safety Profile of AFC1 In Vivo
To determine the safety of AFC1 in vivo, we evaluated 
the pathology of liver, kidney, spleen, and lung from mice 
administrated with AFC1 compound for 14 days. As shown 
by Figure 1A, there are no significant morphological changes 
in these organs. Besides, AFC1 administration did not change 
the body weight of mice on day 14 (Figure 1B). Previous study 
showed the cytotoxic effect of TSA on human umbilical vein 
endothelial cells (HUVECs) in a dose-dependent manner 
(Nizamutdinova et al., 2012). Then we treated the HUVECs 
with AFC1 or TSA. MTT data showed no difference in 
HUVECs viability between AFC1 and TSA group when both 
concentrations are 0.1, 1.0, and 3.0 µM (Figure 1C). However, 
AFC1 treated cells showed higher viability than the TSA group 
at 10 µM (p < 0.05) (Figure 1C).
Administration of AFC1 Contributed to the 
Recovery of Cardiac Function After MI/R 
in Murine Models
Further cardiac function data showed that both high dose 
AFC1 (14 mg/kg) compound and TSA (5 mg/kg) significantly 
improved the EF and FS and systolic left ventricular interior 
diameters (LVIDs) in MI/R hearts (Figure 1D). However, there 
was no significance when AFC1 and TSA treated groups were 
compared. Then we assessed whether low (7 mg/kg) and high 
dose (14 mg/kg) of AFC1 have equal protective role in murine 
MI/R models. As shown by Figure 1E, only high dose of AFC1 
increased the EF as well as FS and decreased LVIDs compared to 
the MI/R group on day 14 post operation.
AFC1 Compound Attenuated Mi/R-
Induced Cardiac Remodeling
Both dosages of AFC1 reduced the heart to body weight ratio 
(HW/BW) of mice effectively in comparison to MI/R group on 
day 14 (p < 0.0001) (Figure 2A). WGA staining data revealed 
significant myocyte hypertrophy in MI/R group compared to the 
sham (p < 0.0001) and treatment with AFC1 greatly inhibited 
cardiac hypertrophy (p < 0.01 and p < 0.001) (Figures 2B, C). 
Furthermore, AFC1 treated mice showed alleviated cardiac 
fibrosis compared to the mice without treatment on day 14 
following surgery (Figures 2D, E).
Antioxidant and Anti-Inflammatory 
Effects of AFC1 Compound on Infarcted 
Myocardium Following MI/R In Vivo
It is well established that oxidative stress and inflammation 
response contribute to cardiac remodeling and dysfunction 
following MI/R. We then detected the production of ROS in 
TABLE 1 | Quantitative polymerase chain reaction primers.
Gene Forward primer (5’-3’) Reverse primer (5’-3’)
mPDGF-A GAGGAAGCCGAGATACCCC TGCTGTGGATCTGACTTCGAG
mPDGF-B CATCCGCTCCTTTGATGATCTT GTGCTCGGGTCATGTTCAAGT
mPDGFR-α ACACGTTTGAGCTGTCAACC CCCGACCACACAAGAACAGG
mPDGFR-β TTCCAGGAGTGATACCAGCTT AGGGGGCGTGATGACTAGG
mIL-1β CGAGGCTAATAGGCTCATCT GTTTGGAAGCAGCCCTTCAT
mTNF-α AGCCGATGGGTTGTACCTTGTCTA TGAGATAGCAAATCGGCTGACGGT
mIL-6 TGATGCACTTGCAGAAAACA ACCAGAGGAAATTTTCAATAGGC
mGAPDH AACTTTGGCATTGTGGAAGG ACACATTGGGGGTAGGAACA
rPDGF-A TTCTTGATCTGGCCCCCAT TTGACGCTGCTGGTGTTACAG
rPDGF-B GCAAGACGCGTACAGAGGTG GAAGTTGGCATTGGTGCGA
rPDGF-C CAGCAAGTTGCAGCTCTCCA GACAACTCTCTCATGCCGGG
rPDGF-D ATCGGGACACTTTTGCGACT GTGCCTGTCACCCGAATGTT
rPDGFR-α GCTACACGTTTGAGCTGTCAAC ATGGTGGTCATCCACAAGC
rPDGFR-β TCTCTCATCATCCTCATCATGC CCTTCCATCGGATCTCATAGC
rANP GAGGAGAAGATGCCGGTAG CTAGAGAGGGAGCTAAGTG
rα-SKA GCATGCAGAAGGAGATCACA CATAGCACGATGGTCGATTG
rβMHC AGATCGAGGACCTGATGGTG GATGCTCTTCCCAGTTGAGC
rCol Type I CATGTTCAGCTTTGTGGACCT GCAGCTGACTTCAGGGATGT
rCol Type III GGTCACTTTCACTGGTTGACGA TTGAATATCAAACACGCAAGGC
rGAPDH ACAAGATGGTGAAGGTCGGTG AGAAGGCAGCCCTGGTAACC
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hearts of different groups. MI/R significantly increased 
the ROS level, while AFC1 treatment greatly decreased 
ROS accumulation in the infarcted area (p < 0.05) (Figures 
3A, B). Figures 3C and D showed that high dosage of AFC1 
dramatically decreased the CD45+ cell infiltrations in heart 
post MI/R (p < 0.0001). Moreover, both high and low dosages 
of AFC1 compound significantly down-regulated mRNA 
levels of inflammatory cytokines including IL-1β, IL-6, and 
TNF-α in MI/R hearts (Figure 3E). These results suggested 
that AFC1 can attenuate MI/R-induced inflammatory 
responses in the heart.
AFC1 Inhibited the Expression of PDGFR 
in Murine Heart Following MI/R
Previous study revealed that PDGFs are involved in myocardial 
remodeling following infarction (Zhao et al., 2011). To verify 
whether MI/R could lead to an up-regulation of PDGF-related 
signaling, we measured the expression of PDGF-A, PDGF-B, 
and PDGFR isoforms in infarcted myocardium. As shown by 
Figure 4A, 30 min of ischemia followed by 2 weeks reperfusion 
markedly elevated mRNA levels of PDGFRα, -β, PDGF-A, and 
PDGF-B (Figures 4A, B). Next, we treated the MI/R mice with 
AFC1 and data showed high dose of AFC1 down-regulated 
FIGURE 1 | Administration of AFC1 contributed to the recovery of cardiac function after MI/R in murine models. Mice were injected with low (7 mg/kg), high-dosage 
(14 mg/kg) of AFC1 compound or TSA (5 mg/kg) intraperitoneally for 7 days after MI/R (n = 5). (A) Lung, liver, spleen, and kidney sections were harvested on day 
14 for H&E staining. Figures showed the representative data. Magnification was ×50. (B) Body weight change of mice after AFC1 administration was analyzed on 
day 14. (C) HUVECs were seeded at a concentration of 1×104/well in 96-well plate and treated with DMSO, AFC1 compound, or TSA for 24 h. Then cell viability 
was evaluated by MTT assay. (D) EF, FS, and LVIDs were measured by echocardiography on day 14 following MI/R. (E) Average values for EF, FS, and LVIDs. 
Each experiment was repeated for at least three times and results indicated mean ± SEM of one independent experiment. *p < 0.05, **p < 0.01, ***p < 0.001, 
****p < 0.0001 versus sham or selected group; #p < 0.05, ##p < 0.01, ###p < 0.001 versus MI/R. *represent the significant different between MI/R group vs the sham 
group; #represent the significant different between treatment group and MI/R group.
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both PDGFRα and -β mRNA levels in MI/R hearts. Low dose 
of AFC1 also decreased the expression of PDGFRα (p < 0.05). 
However, AFC1 did not affect PDGF-A or PDGF-B expression 
in hearts subjected to MI/R. Then we determined the PDGFRα 
protein level by immunofluorescence. As shown in Figure 4C, 
PDGFRα protein expression in the heart increased after MI/R, 
while it decreased after treatment with AFC1. (Nizamutdinova 
et al., 2012).
Effect of PDGF Stimulation on PDGFR 
Expression in NCM and NCF In Vitro
To further elucidate the role of PDGF signaling on heart 
remodeling, we treated NCM and NCF with different isoforms 
of PDGF for 48 or 72 h in vitro. As shown by Figure 5A, addition 
of PDGF-AA, PDGF-AB, PDGF-BB, or PDGF-CC all increased 
the mRNA levels of PDGFRα in NCM compared to the control 
media. Besides, PDGF-AB or PDGF-BB treatment up-regulated 
the PDGFRβ mRNA expression in NCM (Figure 5B). Figure 
5C showed that NCM stimulated with PDGF-AB, PDGF-BB, 
or PDGF-CC for 48 h showed significant elevation of protein 
content in comparison to control cells. Moreover, administration 
of PDGF-AB or PDGF-BB triggered collagen synthesis in 
NCF (Figure 5D).
AFC1 Reversed the Elevation of PDGFR 
Induced by PDGF-AB in Both NCM and 
NCF In Vitro
Next, we treated NCM and NCF with PDGF-AB and AFC1 to 
determine whether AFC1 compound exerts its protective effect 
via regulating PDGF signaling in vitro. As shown by Figures 6A 
and B, addition of AFC1 greatly decreased both PDGFRα and 
PDGFRβ mRNA expression in NCM stimulated with PDGF-AB. 
Moreover, high dose of AFC1 reversed the up-regulation of 
PDGFRβ mRNA levels induced by PDGF-AB in NCF (Figure 
6C). MTT data (Figure 6D) showed that AFC1 did not affect 
the viabilities of NCF, further confirming that AFC1 inhibits 
the levels of PDGFRα and PDGFRβ stimulated by PDGF-AB in 
viable NCF cells.
FIGURE 2 | AFC1 Compound attenuated MI/R-induced cardiac remodeling. Heart sections were harvested as mentioned above (n = 5). (A) Heart to body weight 
ratio (HW/BW%) was measured on day 14. (B) Representative photomicrographs illustrating ventricular myocyte cross-sections stained WGA. (C) Cross-sectional 
area quantification was shown in statistic graph. (D) Hearts were sliced and stained with Masson’s trichrome to assess fibrosis. (E) Percent of fibrosis area in each 
group was shown in statistics. Each experiment was repeated for at least three times and results indicated mean ± SEM of one independent experiment. **p < 0.01, 
****p < 0.0001 versus sham; ##p < 0.01, ###p < 0.001, ####p < 0.0001 versus MI/R.
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AFC1 Suppressed NCM Hypertrophy 
and NCF Collagen Synthesis Induced 
by PDGF-AB
To determine whether AFC1 compound can inhibit PDGF-AB 
induced NCM hypertrophy and NCF collagen synthesis, we 
examined the protein content via liquid scintillation detector 
to evaluate cardiac remodeling in vitro. Figure 7A showed that 
addition of AFC1 (1.0–10 µM) significantly decreased NCM 
hypertrophy induced by PDGF-AB in a dose-dependent manner. 
Furthermore, AFC1 (3.0 and 10 µM) reversed the elevations of 
ANP, β-MHC, and α-SKA mRNA levels stimulated by PDGF-AB 
in NCM (Figure 7B). AFC1 also inhibited the collagen synthesis 
(Figure 7C) as well as the mRNA expression of Col I and Col III 
in NCF stimulated by PDGF-AB (Figure 7D).
AFC Modulated Signaling Pathways 
Involved in Cardiac Function and MI/R
Previous reports revealed that STAT signaling pathway played a 
vital role in myocardial remodeling (Aboulhoda, 2017, Wincewicz 
and Sulkowski, 2017), and P38MAPK pathway is involved in 
cellular inflammatory response and apoptosis under the condition 
of ischemia and hypoxia (Owona et al., 2013). We cultured NCM 
and NCF with PDGF-AB with or without JAK inhibitor JI1 
(JAKs inhibitor I-Calbiochem, Darmstadt, Germany) and p38 
inhibitor 979 (Cai et al., 2018). As shown by Figures 8A and 
B, both 10 μM JI1 and 3 μM 979 inhibited NCM hypertrophy 
and NCF collagen synthesis induced by PDGF-AB. Western blots 
analysis of protein expression of p-JAK2, p-STAT3, and p-p38 
in cells revealed that PDGF-AB treatment greatly activated the 
phosphorylation of STAT3 in NCM and p-38 in NCF. Addition 
of AFC1 dramatically decreased the levels of p-STAT3 in NCM 
and p-p38 in NCF induced by PDGF-AB (Figures 8C, D). No 
significant difference was observed in the expression of p-JAK2 
in these groups.
For in vivo study, MI/R increased the ratio of p-STAT3/GAPDH 
without affecting p-STAT3/STAT3 and STAT3/GAPDH in infarcted 
myocardium. Treatment with high dose of AFC1 markedly reversed 
the elevation of both p-STAT3/GAPDH and p-STAT3/STAT3 
without affecting the ratio of STAT3/GAPDH (Figures 8E, F).
FIGURE 3 | Antioxidant and anti-inflammatory Effects of AFC1 compound on infarcted myocardium following MI/R in vivo. Heart sections were harvested and 
frozen as mentioned above (n = 5). (A) Reactive oxygen species production was assessed by dihydroethidium (DHE) conversion to red fluorescent ethidium. (B) 
Fluorescence intensity was evaluated to determine ROS level. (C) Immunofluorescence staining of CD45 in transverse section of heart (400×). (D) CD45+ cells were 
quantified in the field. (E) Hearts were homogenized and q-PCR was performed to quantify IL-1β, TNF-α, and IL-6 mRNA levels. Results indicated mean ± SEM of 
one representative experiment and the experiment was repeated three times. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 versus sham; #p < 0.05, ##p < 0.01, 
###p < 0.001, ####p < 0.0001 versus MI/R.
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FIGURE 4 | AFC1 inhibited the expression of PDGFR in heart following MI/R (n = 5). Total RNA was extracted from hearts in each group and q-PCR was performed 
to quantify PDGFRα, PDGFRβ (A), PDGF-A, and PDGF-B (B) mRNA levels. (C) Immunofluorescence staining of PDGFRα in transverse section of heart (400×). Each 
experiment was repeated for at least three times and results indicated mean ± SEM of one representative experiment. *p < 0.05, **p < 0.01, ****p < 0.0001 versus 
sham; #p < 0.05, ##p < 0.01 versus MI/R.
FIGURE 5 | Effect of PDGF stimulation on PDGFR expression in NCM and NCF in vitro. PDGFRα (A) and PDGFRβ (B) mRNA expression in NCM were assessed by 
q-PCR. NCM hypertrophy (C) was measured by 3H-leucine incorporation and NCF collagen synthesis (D) measured by 3H-proline incorporation on different PDGF 
isoform stimulation. Each experiment was repeated for four times and results indicated mean ± SEM of one representative experiment. *p < 0.05, **p < 0.01, ***p < 
0.001, ****p < 0.0001 versus control.
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FIGURE 6 | AFC1 reversed the elevation of PDGFR induced by PDGF-AB in both NCM and NCF in vitro. PDGFR expression in NCM (A, B) and NCF (C) were quantified 
by q-PCR. (D) Viability of NCF stimulated with PDGF-AB or AFC1 compound (0.1, 1.0, 3.0, 10.0 μM) was evaluated by MTT assay. This experiment was repeated four 
times and results indicated mean ± SEM of one independent experiment and representative pictures. **p < 0.01 versus control; #p < 0.05, ##p < 0.01 versus PDGF-AB.
FIGURE 7 | AFC1 suppressed PDGF-AB induced NCM hypertrophy and NCF collagen synthesis. NCM hypertrophy (A) was measured by 3H-leucine incorporation 
and NCF collagen synthesis (C) measured by 3H-proline incorporation on different concentration of AFC1 after PDGF-AB (10 ng/ml) stimulation. mRNA levels of 
ANP, β-MHC, α-SKA in NCM (B), and Col I, Col III in NCF (D) were measured by q-PCR. This experiment was repeated four times and results indicated mean ± 
SEM of one independent experiment. *p < 0.05, **p < 0.01, ****p < 0.0001 versus control; #p < 0.05, ##p < 0.01, ###p < 0.001 versus PDGF-AB.
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DISCUSSION
Early and effective intervention strategies have greatly decreased 
the mortality of IHD; however, reperfusion could cause 
myocardium damage, even exacerbate the cardiac function and 
structure (Wang et al., 2015b). Innovative pharmacotherapies 
to improve the outcomes especially left ventricular remodeling 
in patients who suffered from MI are still an urgent need 
(Della  Rocca et al., 2012; Chew et al., 2018). Recently, TCMs 
have received much attention due to their functions in reduction 
of myocardial injury (Mo et al., 2015; Yang et al., 2016). Many 
studies demonstrated the cardioprotective effect of TSA and 
FIGURE 8 | Continued
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sodium TSA sulfonate in myocardial ischemia/reperfusion injury 
animal models (Zhang et al., 2010; Zhang et al., 2013; Wei et al., 
2014; Li Q et al., 2016; Pan et al., 2017). Results from the recent 
clinical trial indicated that sodium TSA sulfonate in combination 
with current therapies may significantly reduce adverse LV 
remodeling and potentially improve clinical outcomes, providing 
important evidence on the efficacy of sodium TSA sulfonate 
treatment in patients (Mao et al., 2015a; Mao et al., 2015b). 
Another trail named “Sodium Tanshinone IIA Sulfonate in 
Left Ventricular Remodeling Secondary to Acute Myocardial 
Infarction” is going on in Guangzhou, China (ClinicalTrials.gov 
Identifier: NCT02524964)(https://www.clinicaltrials.gov).
We have been searching new TCM-based cardioprotective 
agents and identified series AFC compounds with TSA 
mimic effects. In this study, we reported for the first time the 
cardioprotective actions of AFC1 in murine MI/R models. 
Ventricular remodeling including cardiac hypertrophy and 
fibrosis is the leading cause contributing to cardiac dysfunction 
after MI/R (Konishi et al., 2013). The key findings of the present 
study are that administration of AFC1 effectively reduced the 
cardiac myocyte hypertrophy and fibrosis on day 30 post MI/R, 
accompanied by significant improvement of cardiac function, 
and also inhibited MI/R-induced cardiac remodeling in vivo. The 
effect of AFC1 may be mediated by its inhibition of production of 
ROS and inflammation mediators and regulation of key signaling 
pathways, including PDGF, STAT3, and p38 signaling pathways.
MI/R is a complex multifactorial pathophysiological 
process that oxidative stress and inflammatory response are 
key contributors to the following cardiac remodeling. The 
damage of oxygen free radical on vessel and myocardium after 
perfusion could result in myocardial injury and finally accelerate 
the development of MI/R (Duan et al., 2015). MI/R activated 
sterile inflammatory response characterized by the recruitment 
and activation of immune cells (Yan et al., 2013). Numerous 
studies have demonstrated that inhibition of neutrophil 
recruitment mediated by macrophage reduced tissue damage 
FIGURE 8 | Potential mechanism of the protective function of AFC1 treatment in vitro and in vivo n = 5. After being treated with JI1 (A) or 979 (B) and then 
stimulated with PDGF-AB, NCM hypertrophy was measured by 3H-leucine incorporation and NCF collagen synthesis measured by 3H-proline incorporation. (C, 
D) Protein levels of p-JAK2, p-STAT3 in NCM and p-p38 in NCF were determined via Western blot analysis. (E) Infarct area of heart in each group was lysed and 
p-STAT3, STAT3 protein levels were determined via Western blot. (F) p-STAT3/STAT3, p-STAT3/GAPDH, and STAT3/GAPDH were analyzed with image J software. 
Two or three samples were randomly selected from each group for Western blot experiment. Each experiment was repeated for at least three times and results 
indicated mean ± SEM of one independent experiment and the representative pictures. *p < 0.05, **p < 0.01, ****p < 0.0001 versus control or sham; #p < 0.05, 
##p < 0.01, ###p < 0.001 versus PDGF-AB or MI/R.
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and infarct size in ischemic myocardium (Romson et al., 1983; 
de Lorgeril et al., 1989; Hatori et al., 1991; Li et al., 2016; Wang 
et al., 2016). Excessive neutrophil infiltration in the infarct site 
is detrimental to cardiomyocyte survival for secreting ROS, 
which further aggravates structural damage of tissue (Hansen, 
1995). Our data showed that AFC1 compound inhibited the 
production of ROS, the infiltration of inflammatory cells, as well 
as the content of inflammatory cytokines, such as IL-1β, TNF-
α, and IL-6 in infarcted myocardium, which implied that AFC1 
compound may play an important role in improving ventricular 
remodeling  after  MI/R via suppressing oxidative stress and 
inflammatory responses.
Previously, evidences indicated the crucial role of PDGF on 
stimulating fibrosis in many pathological conditions (Choi et al., 
2005; Fan et al., 2013). Hypoxia could cause murine pulmonary 
vascular medial hypertrophy via increasing PDGF concentration 
(Zhang et al., 2012). PDGF-AB released by myofibroblast could 
cause myocyte structural and electromechanical remodeling 
in ovine persistent atrial fibrillation (PAF) through reducing 
calcium transients (Musa et al., 2013). The expression of PDGF 
is closely related to inflammation and fibrosis in infarcted 
myocardium (Zhao et al., 2011). In addition, PDGF can induce 
ROS production in MEFs (Choi et al., 2005). Therefore, PDGF 
may induce cardiac remodeling following MI/R via promoting 
oxidative stress and inflammatory response. The present 
result showed much higher expressions of PDGF-A, PDGF-B, 
PDGFRα, and PDGFRβ in murine MI/R myocardium in MI/R 
heart than that in the sham group. Previous report from the 
MI rat models (Liu et al., 2014) revealed similar findings. Our 
results further indicated that AFC1 compound can effectively 
decrease the levels of PDGFR without affecting the expression 
of PDGF-A and PDGF-B in the heart post MI/R. Besides, AFC1 
treatment greatly reduced PDGF-AB-stimulated PDGFR mRNA 
expression in NCM and NCF, as well as inhibited PDGF-AB-
stimulated NCM hypertrophy and NCF collagen synthesis in 
vitro. These data suggested that cardio-protective function of 
AFC1 may attribute to the inhibition of PDGFR signaling in vivo 
and in vitro.
It is proved that Janus kinase/signal transduction and 
activators of transcription (JAK/STAT) pathway can be activated 
by ischemic stress stimuli and cardiac hypertrophy agonist 
PDGF (Goodman et al., 2011; Wu et al., 2012). Tyrosine kinase 
could phosphorylate receptor tyrosine residues expressed on 
cardiomyocytes and activate the STAT phosphorylation. The 
activated STAT then transferred to nucleus and bonded to the 
target gene to regulate the expression of transcription factors or 
genes associated with hypertrophy and fibrosis, such as p21waf1 
and c-fibrinogen (Wagner and Siddiqui, 2012). Inhibition of 
JAK/STAT pathway could reduce the myocardial infarct size 
and cardiomyocyte apoptosis induced by MI/R in rat models 
(Mascareno et al., 2001). Besides, PDGF-AB stimulated 
proliferation of human airway smooth muscle cells, which 
contribute to airway remodeling through the JAK/STAT pathway 
(Simon et al., 2002). Studies revealed that the PDGF/PDGFR 
pathway is involved in the regulation of cardiac function and the 
development of ventricular remodeling in MI/R via JAK/STAT 
downstream pathway (Wang et al., 2000; Booz et al., 2002). On 
the other hand, as an important intracellular signaling enzyme, 
P38MAPK is activated by myocardial ischemia and hypoxia 
to induce cellular apoptosis, and results in impaired cardiac 
function and amplifies the inflammatory cascade in the heart 
following MI/R. Our in vitro data showed that stimulation of 
PDGF-AB increased STAT3 phosphorylation in NCM and p38 
phosphorylation in NCF, and addition of AFC1 compound 
significantly decreased both proteins’ phosphorylation, as well 
as suppressed NCM hypertrophy and NCF collagen synthesis. 
Moreover, in murine MI/R models, the expression of p-STAT3 
up-regulated in murine infarcted myocardium and this 
elevation can be dramatically decreased by AFC1 treatment, 
indicating the possible downstream pathway in which AFC1 
exerts its role in cardiac myocyte. We therefore proposed 
that AFC1 compound may attenuate MI/R-induced cardiac 
remodeling via regulating PDGFR signaling and inhibiting the 
phosphorylation of STAT3. It is also possible that AFC1 may 
act on other singling pathways, but further study is needed to 
elucidate this.
Importantly, AFC1 showed neither detrimental impact on 
morphological and histological changes of murine lung, liver, 
kidney, and spleen, nor the cytotoxicity in HUVEC viability. It 
showed less cytotoxicity than TSA in high doses, indicating it 
may have a better safety profile than TSA. Since TSA has been 
widely used clinically with excellent safety profile, AFC1 may 
also be a potential clinical agent for treating MI/R. But further 
study is needed on its pharmacokinetic profile and more detailed 
evaluation of its toxicity in vivo. In addition, further investigations 
are needed to explore the role of AFC1 in other cardiovascular 
diseases and further in clinical trials.
CONCLUSIONS
AFC1 compound had comparable effect with TSA in improving 
cardiac function after MI/R. Administration of AFC1 suppressed 
STAT signaling and attenuated MI/R-induced cardiac remodeling 
in murine MI/R models. AFC1 suppressed PDGF-AB induced 
NCM hypertrophy via STAT3 pathway and NCF collagen 
synthesis through p38 signaling. Therefore, AFC1 may be a novel 
therapeutic option with anti-hypertrophic and anti-fibrotic 
effect against MI/R-induced cardiac remodeling in patients who 
suffered from MI/R.
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